J
Jacoline E C Bromberg
Researcher at Erasmus University Rotterdam
Publications - 103
Citations - 10921
Jacoline E C Bromberg is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Primary central nervous system lymphoma & Rituximab. The author has an hindex of 31, co-authored 95 publications receiving 9357 citations. Previous affiliations of Jacoline E C Bromberg include Erasmus University Medical Center & Utrecht University.
Papers
More filters
Journal ArticleDOI
Acute painful lumbosacral paresthesia after intrathecal rituximab
Jacoline E C Bromberg,J.K. Doorduijn,Joke W. Baars,van Gustaaf Imhoff,Roeline Enting,M. J. van den Bent +5 more
TL;DR: In this article, the authors designed a phase-II study to evaluate an intensive protocol including myeloablative treatment in CNS recurrence of systemic B-cell non-Hodgkin's lymphoma (NHL).
Journal ArticleDOI
The Role of Rituximab in Primary Central Nervous System Lymphoma
TL;DR: Although the evidence of the benefit of rituximab is limited, it is already incorporated into many treatment regimens, both in studies and in standard clinical practice, and should be weighed against the increased costs of the treatment.
Journal ArticleDOI
The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma.
TL;DR: In this paper, the authors reflect on the available evidence of the use of rituximab in PCNSL and conclude that whether it has any beneficial effect remains uncertain.
Journal ArticleDOI
MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma.
Matthijs van der Meulen,Linda Dirven,Katerina Bakunina,Martin J. van den Bent,Samar Issa,Jeanette K. Doorduijn,Jacoline E C Bromberg +6 more
TL;DR: In this article, the authors assess the value of the Mini-Mental State Examination (MMSE)-score at baseline in predicting survival in adult primary central nervous system lymphoma (PCNSL) patients.
Journal ArticleDOI
Treatment of Secondary Central Nervous System Lymphoma with Intrathecal Rituximab, High Dose Methotrexate and R-DHAP, Followed by Autologous Stem Cell Transplantation. A Phase II HOVON Study
Jeanette Doorduyn,Gustaaf W. van Imhoff,Kees van Montfort,Harry C. Schouten,M. R. Schaafsma,Johanna W. Baars,Marie José Kersten,Elly Lugtenburg,Martin M. J. van den Bent,Roelien H. Enting,Philip Poortmans,Jacoline E C Bromberg +11 more
TL;DR: The feasibility and efficacy of a new treatment regimen consisting of the standard treatment of relapsed DLBCL (R-DHAP and autologous stem cell transplantation (ASCT) combined with intrathecal rituximab and high dose methotrexate (MTX) intravenously is studied.